Dermatology

1-16 of 17

• 

  CME/CE In-Person & Virtual Event

  Clear Skin, Clear Path: Transforming Psoriasis Care with Durable Biologic and Oral IL-23 Innovations

  June 12, 2026
  Denver, Colorado

  1.00 credit

• 

  RestartResume

  When Topicals Fail: The New IPC Consensus Every Clinician Should Know

  RestartResume

  When Topicals Fail: The New IPC Consensus Every Clinician Should Know

  CME/CE

  When Topicals Fail: The New IPC Consensus Every Clinician Should Know

  Linda Stein Gold, MD; Bruce Strober, MD, PhD

  0.25 credits

  • 

    

    Linda Stein Gold, MD

  • 

    

    Bruce Strober, MD, PhD

  0.25 credits

• 

  RestartResume

  Pruritus In PN and AD: Challenge How You Manage Itch

  RestartResume

  Pruritus In PN and AD: Challenge How You Manage Itch

  CME/CE

  Pruritus In PN and AD: Challenge How You Manage Itch

  Peter A. Lio, MD

  1.00 credit

  • 

    

    Peter A. Lio, MD

  1.00 credit

• 

  RestartResume

  Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma

  RestartResume

  Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma

  MinuteCE®

  Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma

  John M. Kirkwood, MD; Sapna Patel, MD

  1.00 program credit

  • 

    

    John M. Kirkwood, MD

  • 

    

    Sapna Patel, MD

  1.00 program credit

• 

  RestartResume

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma

  RestartResume

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma

  MinuteCE®

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma

  Paolo A. Ascierto, MD; Hussein Tawbi, MD, PhD

  1.00 program credit

  • 

    

    Paolo A. Ascierto, MD

  • 

    

    Hussein Tawbi, MD, PhD

  1.00 program credit

• 

  MinuteCE®

  Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma

  John M. Kirkwood, MD; Paolo A. Ascierto, MD

  1.00 credit 10 episodes

  • 

    

    John M. Kirkwood, MD

  • 

    

    Paolo A. Ascierto, MD

  • 

    

    Hussein Tawbi, MD, PhD

  • 

    

    Sapna Patel, MD

  1.00 credit 10 episodes

• 

  RestartResume

  Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma

  RestartResume

  Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma

  MinuteCE®

  Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma

  Hussein Tawbi, MD, PhD; Sapna Patel, MD

  1.00 program credit

  • 

    

    Hussein Tawbi, MD, PhD

  • 

    

    Sapna Patel, MD

  1.00 program credit

• 

  RestartResume

  Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma

  RestartResume

  Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma

  MinuteCE®

  Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma

  John M. Kirkwood, MD; Sapna Patel, MD

  1.00 program credit

  • 

    

    John M. Kirkwood, MD

  • 

    

    Sapna Patel, MD

  1.00 program credit

• 

  RestartResume

  Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma

  RestartResume

  Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma

  MinuteCE®

  Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma

  Paolo A. Ascierto, MD; Hussein Tawbi, MD, PhD

  1.00 program credit

  • 

    

    Paolo A. Ascierto, MD

  • 

    

    Hussein Tawbi, MD, PhD

  1.00 program credit

• 

  RestartResume

  Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma

  RestartResume

  Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma

  MinuteCE®

  Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma

  Sapna Patel, MD; John M. Kirkwood, MD

  1.00 program credit

  • 

    

    Sapna Patel, MD

  • 

    

    John M. Kirkwood, MD

  1.00 program credit

• 

  RestartResume

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma

  RestartResume

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma

  MinuteCE®

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma

  Hussein Tawbi, MD, PhD; Sapna Patel, MD

  1.00 program credit

  • 

    

    Hussein Tawbi, MD, PhD

  • 

    

    Sapna Patel, MD

  1.00 program credit

• 

  RestartResume

  Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management

  RestartResume

  Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management

  MinuteCE®

  Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management

  Hussein Tawbi, MD, PhD; Paolo A. Ascierto, MD

  1.00 program credit

  • 

    

    Hussein Tawbi, MD, PhD

  • 

    

    Paolo A. Ascierto, MD

  1.00 program credit

• 

  RestartResume

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma

  RestartResume

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma

  MinuteCE®

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma

  Paolo A. Ascierto, MD

  1.00 program credit

  • 

    

    Paolo A. Ascierto, MD

  1.00 program credit

• 

  RestartResume

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma

  RestartResume

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma

  MinuteCE®

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma

  Paolo A. Ascierto, MD; Hussein Tawbi, MD, PhD

  1.00 program credit

  • 

    

    Paolo A. Ascierto, MD

  • 

    

    Hussein Tawbi, MD, PhD

  1.00 program credit

• 

  RestartResume

  A Clear Horizon in Plaque Psoriasis: Exploring the Role of Investigational Oral Therapies

  RestartResume

  A Clear Horizon in Plaque Psoriasis: Exploring the Role of Investigational Oral Therapies

  CME/CE

  A Clear Horizon in Plaque Psoriasis: Exploring the Role of Investigational Oral Therapies

  0.25 credits

  0.25 credits

• 

  RestartResume

  Patient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities

  RestartResume

  Patient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities

  CME/CE

  Patient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities

  Jonathan Leventhal, MD; Shahnaz Singh-Kandah, NP

  0.25 credits

  • 

    

    Jonathan Leventhal, MD

  • 

    

    Shahnaz Singh-Kandah, NP

  0.25 credits

• Prev
• 1
• 2
• Next